Baseline demographics of the Valsartan Heart Failure Trial

Val-HeFT Investigators

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale randomized, multinational clinical study to assess the efficacy and safety of valsartan, an angiotensin II receptor blocker, added to conventional therapy, including angiotensin-converting enzyme inhibitors, in heart failure patients. A total of 5010 patients with an ejection fraction < 40% have been randomized to either valsartan titrated to 160 mg b.i.d. or to placebo. Aims: Baseline characteristics of patients in Val-HeFT are presented and compared with other major clinical trials in heart failure. Methods: Baseline data were collected and summary statistics calculated. Results: The Study population has a mean age of 62.7 years and is 80% male, 90.3% white, 6.9% black, and 2.8% Asian. Antecedent coronary heart disease is reported in 57.2% of patients. Angiotensin-converting enzyme inhibitors are prescribed for 92.7% of patients, diuretics for 85.8%, digoxin for 67.3%, and β-blockers for 35.6%. Subgroup comparisons by age, sex, race and ejection fraction quartile show small differences in baseline characteristics. Conclusion: Overall the Val-HeFT population is generally representative of the population of patients with mild to moderate heart failure in industrialized countries. (C) 2000 European Society of Cardiology.

Original languageEnglish (US)
Pages (from-to)439-446
Number of pages8
JournalEuropean Journal of Heart Failure
Volume2
Issue number4
DOIs
StatePublished - Jan 1 2000

Fingerprint

Valsartan
Heart Failure
Demography
Angiotensin-Converting Enzyme Inhibitors
Population
Patient Advocacy
Angiotensin Receptor Antagonists
Digoxin
Diuretics
Developed Countries
Coronary Disease
Placebos
Clinical Trials

Keywords

  • Angiotensin receptor blocker
  • Baseline demographics
  • Clinical trial
  • Heart failure
  • Valsartan

Cite this

Baseline demographics of the Valsartan Heart Failure Trial. / Val-HeFT Investigators.

In: European Journal of Heart Failure, Vol. 2, No. 4, 01.01.2000, p. 439-446.

Research output: Contribution to journalArticle

Val-HeFT Investigators. / Baseline demographics of the Valsartan Heart Failure Trial. In: European Journal of Heart Failure. 2000 ; Vol. 2, No. 4. pp. 439-446.
@article{684d55b9c79a4682835cffbe7c3ba696,
title = "Baseline demographics of the Valsartan Heart Failure Trial",
abstract = "Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale randomized, multinational clinical study to assess the efficacy and safety of valsartan, an angiotensin II receptor blocker, added to conventional therapy, including angiotensin-converting enzyme inhibitors, in heart failure patients. A total of 5010 patients with an ejection fraction < 40{\%} have been randomized to either valsartan titrated to 160 mg b.i.d. or to placebo. Aims: Baseline characteristics of patients in Val-HeFT are presented and compared with other major clinical trials in heart failure. Methods: Baseline data were collected and summary statistics calculated. Results: The Study population has a mean age of 62.7 years and is 80{\%} male, 90.3{\%} white, 6.9{\%} black, and 2.8{\%} Asian. Antecedent coronary heart disease is reported in 57.2{\%} of patients. Angiotensin-converting enzyme inhibitors are prescribed for 92.7{\%} of patients, diuretics for 85.8{\%}, digoxin for 67.3{\%}, and β-blockers for 35.6{\%}. Subgroup comparisons by age, sex, race and ejection fraction quartile show small differences in baseline characteristics. Conclusion: Overall the Val-HeFT population is generally representative of the population of patients with mild to moderate heart failure in industrialized countries. (C) 2000 European Society of Cardiology.",
keywords = "Angiotensin receptor blocker, Baseline demographics, Clinical trial, Heart failure, Valsartan",
author = "{Val-HeFT Investigators} and Cohn, {Jay N.} and Gianni Tognoni and Robert Glazer and Dirk Spormann",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S1388-9842(00)00130-6",
language = "English (US)",
volume = "2",
pages = "439--446",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Baseline demographics of the Valsartan Heart Failure Trial

AU - Val-HeFT Investigators

AU - Cohn, Jay N.

AU - Tognoni, Gianni

AU - Glazer, Robert

AU - Spormann, Dirk

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale randomized, multinational clinical study to assess the efficacy and safety of valsartan, an angiotensin II receptor blocker, added to conventional therapy, including angiotensin-converting enzyme inhibitors, in heart failure patients. A total of 5010 patients with an ejection fraction < 40% have been randomized to either valsartan titrated to 160 mg b.i.d. or to placebo. Aims: Baseline characteristics of patients in Val-HeFT are presented and compared with other major clinical trials in heart failure. Methods: Baseline data were collected and summary statistics calculated. Results: The Study population has a mean age of 62.7 years and is 80% male, 90.3% white, 6.9% black, and 2.8% Asian. Antecedent coronary heart disease is reported in 57.2% of patients. Angiotensin-converting enzyme inhibitors are prescribed for 92.7% of patients, diuretics for 85.8%, digoxin for 67.3%, and β-blockers for 35.6%. Subgroup comparisons by age, sex, race and ejection fraction quartile show small differences in baseline characteristics. Conclusion: Overall the Val-HeFT population is generally representative of the population of patients with mild to moderate heart failure in industrialized countries. (C) 2000 European Society of Cardiology.

AB - Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale randomized, multinational clinical study to assess the efficacy and safety of valsartan, an angiotensin II receptor blocker, added to conventional therapy, including angiotensin-converting enzyme inhibitors, in heart failure patients. A total of 5010 patients with an ejection fraction < 40% have been randomized to either valsartan titrated to 160 mg b.i.d. or to placebo. Aims: Baseline characteristics of patients in Val-HeFT are presented and compared with other major clinical trials in heart failure. Methods: Baseline data were collected and summary statistics calculated. Results: The Study population has a mean age of 62.7 years and is 80% male, 90.3% white, 6.9% black, and 2.8% Asian. Antecedent coronary heart disease is reported in 57.2% of patients. Angiotensin-converting enzyme inhibitors are prescribed for 92.7% of patients, diuretics for 85.8%, digoxin for 67.3%, and β-blockers for 35.6%. Subgroup comparisons by age, sex, race and ejection fraction quartile show small differences in baseline characteristics. Conclusion: Overall the Val-HeFT population is generally representative of the population of patients with mild to moderate heart failure in industrialized countries. (C) 2000 European Society of Cardiology.

KW - Angiotensin receptor blocker

KW - Baseline demographics

KW - Clinical trial

KW - Heart failure

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=0034535686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034535686&partnerID=8YFLogxK

U2 - 10.1016/S1388-9842(00)00130-6

DO - 10.1016/S1388-9842(00)00130-6

M3 - Article

C2 - 11113722

AN - SCOPUS:0034535686

VL - 2

SP - 439

EP - 446

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 4

ER -